Analysis Suggests China No Longer Huge Cash Cow For Global Pharmas
This article was originally published in PharmAsia News
Executive Summary
An analysis of 60 health-care companies operating in China indicates they are finding the profit margins they had expected in the huge market have been squeezed by the nation's crackdown on compliance issues.